Intraocular Tumors
Schedule Today
Symptoms and Diagnosis
Many eye tumors cause no symptoms in their early stages, which is why regular eye exams are so important. Our retina specialists use state-of-the-art diagnostic equipment to accurately identify and assess any suspicious growths.
While many eye tumors cause no early symptoms, you should see an eye specialist right away if you notice:
- Blurred or distorted vision that glasses cannot fix
- New floaters, flashing lights, or dark spots in your vision
- Loss of side vision or blind spots
- Changes in the size or shape of your pupil
- Eye pain or pressure that does not go away
- A white reflection in a child's pupil in photographs
- Sudden increase in floaters or a curtain-like shadow over your vision (which can indicate a retinal detachment that may be associated with a tumor)
- Changes in the color or appearance of your iris
We use the most advanced imaging technology available to get a complete picture of any tumor:
- Detailed examination by our fellowship-trained retina specialists
- Optical coherence tomography (OCT) for high-resolution cross-sectional images
- Fluorescein angiography to study blood flow in the eye
- Indocyanine green angiography (ICGA) to evaluate choroidal vasculature
- Standardized A-scan and 10-MHz B-scan ultrasound for posterior uveal tumors
- Ultrasound biomicroscopy (UBM) for detailed imaging of iris and ciliary body tumors
- Ultra-widefield photography to capture images of most of the retina
- Specialized tumor photography for precise documentation
- Three-dimensional imaging and cine loops on select systems for accurate tumor mapping
- OCT-angiography to visualize flow patterns in and around some lesions, recognizing it does not replace dye angiography in tumor work-ups
For uveal melanoma, 15-gene expression profiling (DecisionDx-UM) stratifies tumors into Class 1 (lower metastatic risk) and Class 2 (higher metastatic risk). Additional markers such as PRAME status and chromosomal changes (like monosomy 3 and 8q gain) further refine prognosis; testing is typically performed on tumor tissue obtained via fine-needle aspiration biopsy during plaque placement or from an enucleation specimen, and gene expression profiling and cytogenetics provide complementary information to guide follow-up.
We use established medical guidelines to classify tumors based on their size, location, and genetic features. This classification system helps us predict how the tumor might behave and choose the most appropriate treatment approach. Combining traditional measurements with genetic information gives us the most accurate picture possible.
Not every dark spot or growth in the eye is a tumor. Our specialists are experts at distinguishing true tumors from other conditions like bleeding, inflammation, or age-related changes. This expertise is crucial for avoiding unnecessary treatment while ensuring real tumors are not missed.
If you experience any new vision changes, eye pain, or notice unusual spots or growths in your eye, contact our office immediately. Early evaluation by our retina specialists can make a significant difference in your treatment options and outcomes.
Treatment Options
Treatment for eye tumors depends on the type, size, location, and genetic features of the tumor. Our goal is always to preserve your vision and eye while effectively treating the tumor using the most advanced techniques available.
Many small, stable tumors can be safely watched with regular exams and imaging. Our advanced monitoring techniques can detect even tiny changes over time. This approach allows us to intervene quickly if a tumor starts to grow while avoiding unnecessary treatment for stable lesions.
This eye-saving treatment involves placing a small radioactive disc against the eye wall near the tumor. The radiation destroys cancer cells while preserving the eye and often maintaining vision. Customized iodine-125 or ruthenium-106 plaques are selected based on tumor characteristics to achieve high local control while minimizing damage to healthy tissue.
Several types of laser therapy can treat eye tumors effectively. Transpupillary thermotherapy uses infrared laser light to heat and selectively destroy tumor cells and is primarily adjunctive in modern practice, used for carefully selected small lesions or combined with other treatments.
This treatment uses a light-sensitive medication that is activated by laser light to selectively destroy abnormal tissue. Photodynamic therapy with verteporfin is particularly effective for circumscribed choroidal hemangioma and select vascular tumors, with a limited role in uveal melanoma.
Cryotherapy uses extreme cold to destroy tumor cells and is particularly useful for certain types of tumors, especially in children with retinoblastoma. It is most effective for small peripheral lesions and often used as part of multimodal therapy.
For retinoblastoma and select pediatric tumors, chemotherapy may be delivered locally or systemically depending on the disease pattern and goals of care:
- Intravitreal melphalan or topotecan for vitreous seeds
- Ophthalmic artery chemosurgery (melphalan-based) for globe-salvage therapy
- Intravenous chemotherapy for advanced or extraocular/high-risk disease
- Nanoparticle delivery systems remain investigational
Surgery may be needed for tumor biopsy, removal of certain tumors, or treatment of complications. Highly specialized procedures such as trans-scleral resection or endoresection are reserved for select cases at experienced centers and are not first-line for most melanomas.
For eligible patients with unresectable or metastatic disease, tebentafusp is an approved therapy for those who are HLA-A*02:01 positive and has been shown to improve survival in this subgroup; other systemic options are coordinated with medical oncology based on individual factors.
We participate in clinical trials testing new treatments for eye tumors:
- Targeted drug delivery systems that address specific tumor genes
- Immunotherapy approaches under investigation
- Virus-based therapies designed to destroy tumor cells
- Combination treatments that use multiple approaches together
Prevention and Risk Reduction
While not all eye tumors can be prevented, understanding risk factors and taking protective measures may help reduce your chances of developing certain eye conditions and support overall ocular health.
Wearing high-quality sunglasses that block both UVA and UVB rays supports ocular surface and lens health. Choose sunglasses that wrap around your face to block light from all angles, and consider wide-brimmed hats for additional protection.
Regular comprehensive eye exams are the best strategy for early detection, which improves the chance of eye- and vision-sparing treatment. People with risk factors may need more frequent exams or specialized monitoring by a retina specialist.
If you have a family history of eye cancer or certain genetic syndromes, genetic counseling can help assess your risk and develop an appropriate screening plan. For conditions like retinoblastoma, genetic testing can identify family members who need special monitoring.
People with personal or family history of melanoma, certain genetic conditions, or previous eye problems may need enhanced surveillance. We develop individualized monitoring plans that may include more frequent exams, specialized imaging, or genetic testing.
Learning to recognize potential warning signs helps ensure prompt evaluation of any concerning changes. We educate our patients about what to watch for and encourage them to contact us immediately if they notice any vision changes or other symptoms.
Being aware of occupational hazards, environmental exposures, and lifestyle factors that may increase eye risk allows for better prevention strategies. We discuss relevant risk factors with each patient and provide personalized recommendations for risk reduction.
Advanced Technology and Research
Retina Consultants, PA stays at the forefront of eye tumor diagnosis and treatment by incorporating the latest technological advances and participating in research to benefit our patients.
Our ultra-widefield cameras can photograph approximately 80–82% of the retina in a single image, far more than traditional cameras. This technology helps us detect tumors in the far periphery of the eye that might otherwise be missed and provides better monitoring of tumor changes over time.
We use advanced ultrasound equipment, including standardized A-scan and 10-MHz B-scan for posterior uveal tumors and high-frequency UBM for anterior segment lesions; select systems provide three-dimensional reconstructions. These capabilities are crucial for treatment planning and monitoring treatment response.
Optical coherence tomography creates detailed cross-sectional images of the retina and can show how tumors affect surrounding tissue. OCT-angiography can visualize flow patterns in some lesions but does not replace dye angiography in tumor evaluation.
We offer advanced genetic testing for eye tumors, including gene expression profiling that predicts tumor behavior and metastatic risk. This information allows us to provide personalized treatment recommendations and develop appropriate surveillance plans for each patient.
We are incorporating artificial intelligence tools that can help detect subtle changes in tumors and assist our specialists in making more accurate diagnoses. AI technology is particularly helpful for monitoring tumor growth and predicting treatment response.
Our radiation therapy resources include specialized plaques designed for different tumor locations and shapes. Computer-aided treatment planning helps optimize radiation delivery while minimizing damage to healthy eye tissue, and real-time monitoring supports precise plaque placement.
We actively participate in national and international research studies investigating new treatments for eye tumors. This involvement gives our patients access to experimental therapies and helps advance the field of ocular oncology for future patients.
We use secure telemedicine technology to provide follow-up care and consultation services, especially helpful for patients who live far from our offices. Remote monitoring complements, rather than replaces, periodic in-person dilated exams and ultrasound assessments.
Prognosis and Long-Term Outlook
Understanding what to expect after eye tumor treatment helps patients and families plan for the future. Modern treatment methods have significantly improved outcomes for many types of eye tumors, though visual results depend on tumor size and location.
Eye-sparing treatments for choroidal melanoma achieve excellent local control rates, with 93–98% of tumors successfully treated without removing the eye. Vision preservation rates have improved with modern techniques when tumors are detected early and located away from critical structures.
Visual outcomes vary by tumor size and proximity to the macula or optic nerve. Many patients maintain functional vision, but radiation-related complications such as maculopathy or optic neuropathy can reduce vision over time; proactive monitoring and timely therapies like anti-VEGF injections can help.
Genetic testing provides crucial information about the likelihood of tumor spread. Class 1 tumors have lower metastatic risk, while Class 2 tumors require more intensive monitoring for metastatic disease. This information guides our surveillance recommendations.
Most patients return to their normal activities after eye tumor treatment with minimal long-term restrictions. Modern rehabilitation services help patients adapt to any vision changes. Support services and low vision aids help maintain independence and quality of life.
Follow-up care is tailored to each patient's risk level based on tumor genetics and treatment type. Higher-risk patients (such as those with Class 2 or monosomy 3) often need liver-focused surveillance, MRI when possible or ultrasound with labs, every 3–6 months for at least five years, while lower-risk patients may extend to 6–12 month intervals per oncology guidance.
Modern treatment techniques minimize complications, but some side effects may occur. We have specialized protocols for managing radiation-related problems and can provide treatments like anti-VEGF injections for radiation-induced blood vessel problems. Most side effects can be successfully managed when they occur.
Frequently Asked Questions
Here are answers to the most common questions our patients ask about eye tumors and their treatment.
No, many eye tumors are benign and only require monitoring. The majority of suspicious spots we evaluate turn out to be benign nevi (moles) or other non-cancerous growths. Even when tumors are cancerous, many can be successfully treated while preserving the eye and vision.
The exact cause varies by tumor type and is often unknown. Genetic factors play a role in some cases, while environmental influences may contribute to others. Age and certain medical conditions can also increase risk, and most people who develop eye tumors have no obvious risk factors.
Eye melanoma most commonly affects adults between 50–70 years old, particularly those with fair skin and light eyes. People with a personal or family history of melanoma have higher risk, though eye tumors can occur at any age and in people of all backgrounds.
Not necessarily. Many small tumors cause no vision problems, especially if detected and treated early. The effect on vision depends on the tumor's size, location, and type. Modern treatments are designed to preserve vision whenever possible.
No, surgery is not always necessary. Many tumors can be treated with radiation, laser therapy, or other non-surgical methods. Some small, stable tumors only need careful monitoring. Treatment decisions are individualized based on many factors including tumor characteristics and patient preferences.
Your evaluation will include a comprehensive eye exam, detailed imaging studies like ultrasound and OCT, and photographs of your eye. The visit typically takes 1–2 hours and includes plenty of time to discuss findings and answer questions. We explain everything as we go along.
Follow-up schedules depend on your specific situation. Patients with stable, benign tumors may only need annual visits, while those with treated cancers may need more frequent monitoring. We develop individualized surveillance plans based on tumor genetics and risk factors.
Most treatments are performed with local anesthesia to minimize discomfort. Laser treatments may cause mild discomfort during the procedure, but this is usually well-tolerated. Surgical procedures are performed under anesthesia, so patients feel no pain during the operation.
Some types of eye cancer, particularly melanoma, can spread to other organs, most commonly the liver. However, many eye tumors never spread beyond the eye. Genetic testing helps us assess the risk of spread and develop appropriate monitoring plans.
Genetic testing examines the tumor's genes to predict its behavior and likelihood of spreading. For uveal melanoma, this information helps determine follow-up care by stratifying metastatic risk and guiding surveillance intensity.
Sometimes, depending on your tumor type and treatment. We may refer you to medical oncologists, genetic counselors, or other specialists as needed. Our team coordinates all aspects of your care to ensure you receive comprehensive treatment.
Yes, we participate in clinical trials investigating new treatments for eye tumors. These may include targeted therapies, immunotherapy approaches, and novel drug delivery systems. We can discuss whether any experimental treatments might be appropriate for your situation.
Genetic testing is a reliable tool for risk stratification in uveal melanoma, helping categorize tumors into lower- and higher-risk groups to guide surveillance and treatment decisions. Results are interpreted alongside clinical and imaging findings.
We provide comprehensive support including patient education, genetic counseling, social work services, psychological support, and connections to support groups. Low vision rehabilitation services are available if needed, and we help coordinate care with other specialists.
Our fellowship-trained retina specialists have extensive experience in diagnosing and coordinating treatment for eye tumors using advanced technology. We offer personalized care, access to clinical trials, and comprehensive support services at convenient locations throughout North Jersey.
Expert Eye Tumor Care in North Jersey
Retina Consultants, PA provides comprehensive diagnosis and treatment coordination for intraocular tumors at our offices in Ridgewood, Belleville, and Jersey City, serving patients throughout Bergen, Essex, and Hudson counties with state-of-the-art technology, personalized care, and access to the latest advances in ocular oncology.